Strategic partnerships Target hospitals, clinics, and infusion centers in the US that require large-scale IVIG and plasma-derived therapies, leveraging Kedrion’s expanding distribution network and recent QIVIGY launches to offer integrated supply solutions and patient access programs.

Rare disease focus Position Kedrion as a preferred partner for patient advocacy groups and research organizations in rare and ultra-rare diseases to co-create patient support initiatives, access programs, and clinical collaborations that drive adoption of plasma-derived therapies.

AI healthcare ties Explore collaborations at AI in healthcare summits and with InstaLILY to develop data-driven patient management, demand forecasting, and clinical decision support offerings that differentiate Kedrion’s portfolio in quality and outcomes.

Integrated manufacturing Highlight Kedrion’s fully integrated international manufacturing network as a value proposition for risk mitigation, faster time-to-market, and consistent supply of IVIG and other plasma-derived products to US distribution partners and specialty pharmacies.

Market expansion signals Capitalize on recent US launches and nationwide distribution of QIVIGY to approach payer networks, MSDs, and specialty distributors with co-branding and reimbursement support programs to accelerate adoption and broaden market reach.